A detailed history of Vision Capital Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Vision Capital Management, Inc. holds 1,965 shares of ABBV stock, worth $459,810. This represents 0.06% of its overall portfolio holdings.

Number of Shares
1,965
Previous 2,114 7.05%
Holding current value
$459,810
Previous $392,000 15.82%
% of portfolio
0.06%
Previous 0.05%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 23, 2025

SELL
$184.85 - $231.54 $27,542 - $34,499
-149 Reduced 7.05%
1,965 $454,000
Q2 2025

Jul 16, 2025

BUY
$170.16 - $206.27 $106,690 - $129,331
627 Added 42.17%
2,114 $392,000
Q1 2025

Apr 30, 2025

SELL
$169.2 - $216.66 $106,088 - $135,845
-627 Reduced 29.66%
1,487 $311,000
Q3 2024

Nov 05, 2024

BUY
$163.84 - $199.33 $346,357 - $421,383
2,114 New
2,114 $417,000
Q1 2019

May 01, 2019

SELL
$77.14 - $90.79 $3.77 Million - $4.44 Million
-48,863 Closed
0 $0
Q4 2018

Jan 10, 2019

BUY
$77.85 - $96.01 $39,158 - $48,293
503 Added 1.04%
48,863 $4.51 Million
Q3 2018

Oct 10, 2018

SELL
$88.91 - $98.84 $20,449 - $22,733
-230 Reduced 0.47%
48,360 $4.57 Million
Q2 2018

Jul 06, 2018

SELL
$89.78 - $106.23 $2,872 - $3,399
-32 Reduced 0.07%
48,590 $4.5 Million
Q1 2018

Apr 23, 2018

SELL
$92.01 - $123.21 $168,562 - $225,720
-1,832 Reduced 3.63%
48,622 $4.6 Million
Q4 2017

Feb 08, 2018

SELL
$89.56 - $98.21 $79,350 - $87,014
-886 Reduced 1.73%
50,454 $4.88 Million
Q3 2017

Nov 09, 2017

BUY
$69.85 - $89.22 $3.59 Million - $4.58 Million
51,340
51,340 $4.56 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $414B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Vision Capital Management, Inc. Portfolio

Follow Vision Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vision Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vision Capital Management, Inc. with notifications on news.